An Update on the 2017 IDSA/SHEA Clinical Practice Guidelines: Focus on the Identification and Treatment of Recurrent C. difficile
March 16, 2018
March 16, 2019
Scroll to the Bottom of this Information to Begin this Course
Sponsored by The Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Merck & Company.
- Physicians — maximum of 0.5 AMA PRA Category 1 Credits™
All other health care professionals completing this course will be issued a statement of participation.
This activity is intended for gastroenterologists, infectious disease specialists and other healthcare professionals that treat C. diff infections.
Statement of Need/Program Overview
Clostridium difficile infection (CDI) is associated with significant morbidity and mortality. Further, recurrence of CDI is common after an initial episode. Although a number of therapies with varying mechanisms of action are available to treat CDI and prevent recurrence, the management of CDI is complex and challenging. Clinicians require up-to-date knowledge of evidence-based treatment of initial and recurrent CDI to reduce its burden and improve clinical outcomes.
Upon completion of this activity, participants should be able to:
- Outline risk factors for recurrent C. difficile infection to consider when selecting treatment
- Discuss available data on the treatment of recurrent C. difficile and how that data was applied to the updated IDSA/SHEA Clinical Practice Guidelines
- Compare and contrast recommendations from the 2017 IDSA/SHEA guidelines with previous versions and recommendations from other organizations
Paul Feuerstadt, MD, FACG
Gastroenterology Center of Connecticut
Assistant Clinical Professor of Medicine
Yale University School of Medicine
Physician Continuing Medical Education
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.
Paul Feuerstadt, MD, FACG
- Consulting Agreements: Merck & Company
- Speakers' Bureau: RedHill Biopharma, Allergan, and Merck & Company
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
Instructions for Participation and Credit
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pre-test, view the online activity, and complete the post-test and evaluation. To receive credit, 75% must be achieved on the post-test. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions about this activity, please contact Katlyn Cooper at firstname.lastname@example.org.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.
Disclosure of Unlabeled Use
The faculty may discuss use of agents not approved for the treatment of CDI.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.